Benevolent Platform Precision Medicine

Target A: Scheduled to transition into Lead Op 4Q21 2020 2021 2022 2023 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Target validation Preparation / Hit ID / Hit expansion Lead Optimisation Advanced Lead selection Candidate profiling Candidate nomination Key programme points: ⚫ Best-in-class programme with no clear literature associating Target A as a potential therapeutic option in NASH Compelling anti-fibrotic In vitro target validation data packing to support utility in treatment of NASH • Rapid progress to identify inhibitors of Target A: biophysical screening data and co-crystal structure in-hand to enable identification of novel chemical matter and transition to Lead Optimisation Benevolent 62 ΑΙ

View entire presentation